 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- dazucorilant (CORT113176) / Corcept Therap
Traumatic stress-induced glucocorticoid signaling and rat behavior (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_6092;
All rats then immediately received infusion of either vehicle or CORT113176, a GR antagonist, and received additional doses for the two days following...The data indicate that infusions of GR antagonist tend to promote expression of fear related behaviors, even when administered several days prior to testing. These studies suggest that the glucocorticoid response to SPS may be required for appropriate processing of fear memories.
- || dazucorilant (CORT113176) / Corcept Therap
New P1 trial: Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants (clinicaltrials.gov) - Jul 10, 2024
P1, N=20, Recruiting, Sponsor: Corcept Therapeutics
- ||| dazucorilant (CORT113176) / Corcept Therap
Enrollment closed: DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Apr 26, 2024
P2, N=249, Active, not recruiting, Sponsor: Corcept Therapeutics
These studies suggest that the glucocorticoid response to SPS may be required for appropriate processing of fear memories. Recruiting --> Active, not recruiting
- || dazucorilant (CORT113176) / Corcept Therap
Trial completion date, Trial primary completion date: DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Mar 12, 2024
P2, N=228, Recruiting, Sponsor: Corcept Therapeutics
Recruiting --> Active, not recruiting Trial completion date: Nov 2027 --> May 2027 | Trial primary completion date: May 2027 --> Oct 2024
- | dazucorilant (CORT113176) / Corcept Therap
Preclinical, Journal: Glucocorticoid receptor antagonist CORT113176 attenuates motor and neuropathological symptoms of Huntington's disease in R6/2 mice. (Pubmed Central) - Feb 26, 2024
In female mice, we did not observe major effects of CORT113176 treatment on HD-related symptoms, with the exception of the anti-epileptic effects. We conclude that CORT113176 effectively delays several key symptoms related to the HD phenotype in male R6/2 mice and believe that GR antagonism may be a possible treatment option.
- || dazucorilant (CORT113176) / Corcept Therap
Trial completion date, Trial primary completion date: DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Feb 22, 2024
P2, N=198, Recruiting, Sponsor: Corcept Therapeutics
We conclude that CORT113176 effectively delays several key symptoms related to the HD phenotype in male R6/2 mice and believe that GR antagonism may be a possible treatment option. Trial completion date: Nov 2024 --> Nov 2027 | Trial primary completion date: May 2024 --> May 2027
- | dazucorilant (CORT113176) / Corcept Therap
Journal: Stress-induced Neuroinflammation of the Spinal Cord is Restrained by Cort113176 (Dazucorilant), A Specific Glucocorticoid Receptor Modulator. (Pubmed Central) - Aug 11, 2023
The effects of CORT113176 indicate that glucocorticoids are probably involved in neuroinflammation. Thus, modulation of the GR would become useful to dampen the inflammatory component of neurodegenerative disorders.
- ||| dazucorilant (CORT113176) / Corcept Therap
Enrollment open: DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jan 12, 2023
P2, N=198, Recruiting, Sponsor: Corcept Therapeutics
Thus, modulation of the GR would become useful to dampen the inflammatory component of neurodegenerative disorders. Not yet recruiting --> Recruiting
- |||| dazucorilant (CORT113176) / Corcept Therap
New P2 trial: DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jun 7, 2022
P2, N=198, Not yet recruiting, Sponsor: Corcept Therapeutics
- | CORT113176 / Corcept Therap, Mifeprex (mifepristone) / Danco Laboratories
Preclinical, Journal, Heterogeneity: Corticosterone Levels and Glucocorticoid Receptor Gene Expression in High Drinking in the Dark Mice and Their Heterogeneous Stock (HS/NPT) Founder Line. (Pubmed Central) - Jun 4, 2022
Together, these data suggest that selective breeding for high BALs may have altered stress signaling in the HDID-1 mice, which may contribute to the observed selective efficacy of GR antagonism in reducing binge-like ethanol intake in HDID-1, but not HS/NPT mice. These data have important implications for the role that stress signaling plays in the genetic risk for binge drinking.
- | CORT113176 / Corcept Therap
Preclinical, Journal: Glucocorticoid receptor antagonist alters corticosterone and receptor sensitive mRNAs in the hypoxic neonatal rat. (Pubmed Central) - Dec 29, 2021
We show that CORT113176 variably augments the stress-induced increases in corticosterone concentrations (attenuation of negative feedback) and that GR is critical for hepatic responses to stress in the hypoxic neonate. We also propose that measurement of Gilz and Per1 mRNA expression may be useful to evaluate the effectiveness of GR antagonism.
- || dazucorilant (CORT113176) / Corcept Therap
Trial completion: Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants (clinicaltrials.gov) - Nov 24, 2021
P1, N=6, Completed, Sponsor: Corcept Therapeutics
We also propose that measurement of Gilz and Per1 mRNA expression may be useful to evaluate the effectiveness of GR antagonism. Not yet recruiting --> Completed
- | Preclinical, Journal: Glucocorticoid receptor modulators decrease alcohol self-administration in male rats. (Pubmed Central) - Nov 21, 2021
The mixed glucocorticoid/progesterone receptor antagonist mifepristone and selective GR antagonist CORT113176 have been shown to selectively reduce alcohol consumption in alcohol-dependent rats...The present study tested the effects of the GR modulators CORT118335, CORT122928, CORT108297, and CORT125134 on alcohol self-administration in nondependent (air-exposed) and alcohol-dependent (alcohol vapor-exposed) adult male rats...The present results support the potential of GR modulators for the development of treatments for AUD. Future studies that characterize genomic and nongenomic effects of these GR modulators will elucidate potential molecular mechanisms that underlie alcohol drinking in alcohol-dependent and nondependent states.
- || dazucorilant (CORT113176) / Corcept Therap
Trial completion, Enrollment change: Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants (clinicaltrials.gov) - Oct 10, 2021
P1, N=16, Completed, Sponsor: Corcept Therapeutics
Future studies that characterize genomic and nongenomic effects of these GR modulators will elucidate potential molecular mechanisms that underlie alcohol drinking in alcohol-dependent and nondependent states. Recruiting --> Completed | N=24 --> 16
- || dazucorilant (CORT113176) / Corcept Therap
New P1 trial: Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants (clinicaltrials.gov) - Aug 5, 2021
P1, N=24, Recruiting, Sponsor: Corcept Therapeutics
- || dazucorilant (CORT113176) / Corcept Therap
New P1 trial: Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants (clinicaltrials.gov) - Aug 3, 2021
P1, N=6, Not yet recruiting, Sponsor: Corcept Therapeutics
- ||| dazucorilant (CORT113176) / Corcept Therap
Trial completion: Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants (clinicaltrials.gov) - Oct 12, 2020
P1, N=110, Completed, Sponsor: Corcept Therapeutics
Recruiting --> Completed | N=24 --> 16 Recruiting --> Completed
- ||| dazucorilant (CORT113176) / Corcept Therap
Enrollment open: Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants (clinicaltrials.gov) - Mar 17, 2020
P1, N=122, Recruiting, Sponsor: Corcept Therapeutics
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| dazucorilant (CORT113176) / Corcept Therap
New P1 trial: Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants (clinicaltrials.gov) - Jan 29, 2020
P1, N=122, Not yet recruiting, Sponsor: Corcept Therapeutics